James P Allinson1, Rebecca Hardy2, Gavin C Donaldson1, Seif O Shaheen3, Diana Kuh2, Jadwiga A Wedzicha1. 1. 1 Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 2. 2 MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, United Kingdom; and. 3. 3 Centre for Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Abstract
RATIONALE: Chronic mucus hypersecretion (CMH) is common among smokers and is associated with chronic obstructive pulmonary disease development and progression. OBJECTIVES: To understand how the relationships between smoking, CMH, and chronic obstructive pulmonary disease develop during adult life, and facilitate earlier disease detection and intervention. METHODS: We analyzed data on CMH, smoking, and lung function prospectively collected by the Medical Research Council National Survey of Health and Development, a nationally representative British cohort followed since birth in 1946. We analyzed the longitudinal relationships between smoking and CMH, how symptoms during life related to airflow limitation at 60-64 years, and how CMH duration between ages 43 and 60-64 years related to concurrent FEV1 decline. MEASUREMENTS AND MAIN RESULTS: From 5,362 individuals enrolled at birth, 4,427 contributed data between ages 20 and 64 years (52% male; 63% ever-smoker). Among smokers CMH prevalence escalated between ages 36 and 43 from 7.6 ± 2.0% to 13.0 ± 2.6%. At these ages, symptoms were associated with a higher risk of subsequent airflow limitation (odds ratio [95% confidence interval], 3.70 [1.62-8.45] and 4.11 [1.85-9.13], respectively). Across adult life, CMH followed a dynamic remitting-relapsing course. Symptom prevalence following smoking cessation returned to levels seen among never-smokers. The longer CMH was present across three occasions (ages 43, 53, and 60-64 yr), the greater the concurrent FEV1 decline, corresponding to an additional decrement of 3.6 ± 2.5 ml/yr per occasion that CMH was present (P = 0.005). CONCLUSIONS: CMH among middle-aged smokers represents an early developmental phase of chronic obstructive pulmonary disease. Smoking-related CMH usually resolves following smoking cessation but the longer its duration the greater the FEV1 lost, suggesting the course of CMH across adult life may reflect the underlying course of airway disease activity.
RATIONALE: Chronic mucus hypersecretion (CMH) is common among smokers and is associated with chronic obstructive pulmonary disease development and progression. OBJECTIVES: To understand how the relationships between smoking, CMH, and chronic obstructive pulmonary disease develop during adult life, and facilitate earlier disease detection and intervention. METHODS: We analyzed data on CMH, smoking, and lung function prospectively collected by the Medical Research Council National Survey of Health and Development, a nationally representative British cohort followed since birth in 1946. We analyzed the longitudinal relationships between smoking and CMH, how symptoms during life related to airflow limitation at 60-64 years, and how CMH duration between ages 43 and 60-64 years related to concurrent FEV1 decline. MEASUREMENTS AND MAIN RESULTS: From 5,362 individuals enrolled at birth, 4,427 contributed data between ages 20 and 64 years (52% male; 63% ever-smoker). Among smokers CMH prevalence escalated between ages 36 and 43 from 7.6 ± 2.0% to 13.0 ± 2.6%. At these ages, symptoms were associated with a higher risk of subsequent airflow limitation (odds ratio [95% confidence interval], 3.70 [1.62-8.45] and 4.11 [1.85-9.13], respectively). Across adult life, CMH followed a dynamic remitting-relapsing course. Symptom prevalence following smoking cessation returned to levels seen among never-smokers. The longer CMH was present across three occasions (ages 43, 53, and 60-64 yr), the greater the concurrent FEV1 decline, corresponding to an additional decrement of 3.6 ± 2.5 ml/yr per occasion that CMH was present (P = 0.005). CONCLUSIONS: CMH among middle-aged smokers represents an early developmental phase of chronic obstructive pulmonary disease. Smoking-related CMH usually resolves following smoking cessation but the longer its duration the greater the FEV1 lost, suggesting the course of CMH across adult life may reflect the underlying course of airway disease activity.
Authors: Maria Montes de Oca; Ronald J Halbert; Maria Victorina Lopez; Rogelio Perez-Padilla; Carlos Tálamo; Dolores Moreno; Adrianna Muiño; José Roberto B Jardim; Gonzalo Valdivia; Julio Pertuzé; Ana Maria B Menezes Journal: Eur Respir J Date: 2012-01-26 Impact factor: 16.671
Authors: B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; D S Postma; W Timens Journal: Eur Respir J Date: 2005-11 Impact factor: 16.671
Authors: G Turato; A Di Stefano; P Maestrelli; C E Mapp; M P Ruggieri; A Roggeri; L M Fabbri; M Saetta Journal: Am J Respir Crit Care Med Date: 1995-10 Impact factor: 21.405
Authors: Diana Kuh; Mary Pierce; Judith Adams; John Deanfield; Ulf Ekelund; Peter Friberg; Arjun K Ghosh; Nikki Harwood; Alun Hughes; Peter W Macfarlane; Gita Mishra; Denis Pellerin; Andrew Wong; Alison M Stephen; Marcus Richards; Rebecca Hardy Journal: Int J Epidemiol Date: 2011-02 Impact factor: 7.196
Authors: James P Allinson; Rebecca Hardy; Gavin C Donaldson; Seif O Shaheen; Diana Kuh; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2017-10-15 Impact factor: 21.405
Authors: Yunus Çolak; Shoaib Afzal; Børge G Nordestgaard; Jørgen Vestbo; Peter Lange Journal: Am J Respir Crit Care Med Date: 2020-03-15 Impact factor: 21.405
Authors: Fernando J Martinez; MeiLan K Han; James P Allinson; R Graham Barr; Richard C Boucher; Peter M A Calverley; Bartolome R Celli; Stephanie A Christenson; Ronald G Crystal; Malin Fagerås; Christine M Freeman; Lars Groenke; Eric A Hoffman; Mehmet Kesimer; Kostantinos Kostikas; Robert Paine; Shahin Rafii; Stephen I Rennard; Leopoldo N Segal; Renat Shaykhiev; Christopher Stevenson; Ruth Tal-Singer; Jørgen Vestbo; Prescott G Woodruff; Jeffrey L Curtis; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405
Authors: Mehmet Kesimer; Amina A Ford; Agathe Ceppe; Giorgia Radicioni; Rui Cao; C William Davis; Claire M Doerschuk; Neil E Alexis; Wayne H Anderson; Ashley G Henderson; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando Martinez; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher Journal: N Engl J Med Date: 2017-09-07 Impact factor: 91.245
Authors: S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe Journal: JCI Insight Date: 2016-09-22